Loading company…
Shanghai Waker Biotechnology develops genomic safety tests and analysis tools for gene therapy programs.
Founded in 2021 and based in Shanghai, China, Shanghai Waker Biotechnology develops genomic safety technologies and analytical tools for gene therapy companies and research teams. Its LTA-PCR and TES systems support insertion-mutation risk assessment, CRISPR/Cas9 off-target profiling, and sgRNA selection. The company earns revenue from analysis services, assays, and customized evaluations. In November 2025, it raised CNY 100 million in Series A funding led by Shenzhen Capital Real Estate Fund, with Jinkong Qiyuan Capital participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in